- Advanced search
- Immuno Portal
- Malaria Portal
|Approved drug?||Yes (FDA (2018))|
|International Nonproprietary Names|
|Hu5A8 | ibalizumab-uiyk | TMB-355 | TMB355 | TNX-355 | Trogarzo®|
|Ibalizumab was originally reported as anti-CD4 monoclonal antibody 5A8 by Burkly et al. (1992 ) . It is a non-immunosuppressive, humanised monoclonal antibody that acts as an HIV entry inhibitor [2,4]. Anti-HIV activity of TNX-355 (later to be assigned the INN ibalizumab) in patients was reported in 2004 .
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
|GtoPdb PubChem SID||381744890|
|Search PubMed clinical trials||ibalizumab|
|Search PubMed titles||ibalizumab|
|Search PubMed titles/abstracts||ibalizumab|